Erythema Multiforme Major caused by topical Imiquimod
Main Article Content
Keywords
Erythema Multiforme, Drug reaction
Abstract
Erythema multiforme (EM) is an acute, self-limited inflammatory skin disease that is associated with an immune reaction to various triggers, such as herpes simplex virus, Mycoplasma pneumoniae, and medications. Topically applied medications are a rare cause of EM or EM-like eruptions. We report one patient with EM major from imiquimod 5% topical cream. After reviewing the relevant literature, we found eight cases of erythema multiforme induced by topical imiquimod. Of the eight cases of Imiquimod-induced EM, seven patients had a significant local reaction that subsequently led to the more distant cutaneous manifestations of erythema multiforme. Because Imiquimod is a commonly used topical treatment for a variety of dermatologic conditions, clinicians must be aware of this rare but serious complication. Furthermore, patients with an exuberant local reaction to imiquimod may be at higher risk of developing EM.
References
Hanna E, Abadi R, Abbas O. Imiquimod in dermatology: an overview. Int J Dermatol. 2016; 55(8):831-44.
Yanes DA, Kaffenberger JA, Carr DR. Erythema multiforme as a reaction to imiquimod 5% cream. Dermatol Online J. 2017; 23(2):18.
Pena-Lopez S, Suarez-Magdalena O, Monteagudo B, Cabanillas M. Erythema Multiforme Cause by Treatment With Topical Imiquimod 5% in a Patient With Gorlin Syndrome. Actas Dermosifiliogr. 2018;109:278-281.
Chan M, Kennedy J, Oakley A. Erythema multiforme triggered by imiquimod 5% cream. Australas J Dermatol 2017;58(4):e257-258.
Ballester I, Guijarro J, Niveiro M. Erythema multiforme induced by imiquimod 5% cream. Int J Dermatol. 2014;53:e347-66.
Garcia-Arpa M, Rodriguez-Vazquez M, Delgado Portela M, Vera Iglesias E. Erythema multiforme due to imiquimod 5% cream. Actas Dermosifliogr. 2010; 101:551-71.
Christou E, Morrow C. Erythema multiforme to topical imiquimod 5% cream. Australas J Dermatol. 2012;53:32.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.